KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Buildings (2016 - 2025)

Teva Pharmaceutical Industries filings provide 17 years of Buildings readings, the most recent being $2.3 billion for Q4 2025.

  • On a quarterly basis, Buildings rose 18.24% to $2.3 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.3 billion, a 18.24% increase, with the full-year FY2025 number at $2.3 billion, up 18.24% from a year prior.
  • Buildings hit $2.3 billion in Q4 2025 for Teva Pharmaceutical Industries, up from $2.0 billion in the prior quarter.
  • In the past five years, Buildings ranged from a high of $2.6 billion in Q4 2021 to a low of $2.0 billion in Q4 2024.
  • Median Buildings over the past 5 years was $2.5 billion (2022), compared with a mean of $2.4 billion.
  • Biggest five-year swings in Buildings: dropped 20.9% in 2024 and later rose 18.24% in 2025.
  • Teva Pharmaceutical Industries' Buildings stood at $2.6 billion in 2021, then fell by 4.09% to $2.5 billion in 2022, then grew by 1.02% to $2.5 billion in 2023, then fell by 20.9% to $2.0 billion in 2024, then grew by 18.24% to $2.3 billion in 2025.
  • The last three reported values for Buildings were $2.3 billion (Q4 2025), $2.0 billion (Q4 2024), and $2.5 billion (Q4 2023) per Business Quant data.